ArticleCerebrovascular diseases (Basel, Switzerland)2026
Long-Term Outcomes of Nonsurgical Management Alone for Adult Patients with Ischemic Moyamoya Disease without Cerebral Misery Perfusion: Combined Analyses of Two Prospective Cohorts.
Article in Cerebrovascular diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe most appropriate method to manage adult patients with ischemic-onset moyamoya disease (MMD) without hemodynamic compromise remains undetermined. This study aimed to elucidate the long-term (5- to 10-year) clinical, angiographic, and cognitive outcomes of nonsurgical management alone (including a reduction in atherosclerotic burden by medical treatments and antiplatelet therapy) for adult patients with ischemic MMD without cerebral misery perfusion through combined analyses of two prospective cohorts with the same inclusion criteria.
methodsThe first cohort (71 patients) achieved the 10-year follow-up. The second cohort (55 patients) was followed for ≥5 and ≤10 years. Whether further cerebrovascular events had developed was determined during follow-up. To determine the development of angiographic disease progression and cognitive decline, patients underwent magnetic resonance angiography (MRA) and neuropsychological testing, respectively, at inclusion as well as at last follow-up during or at the end of the 10-year follow-up. Additional MRA was performed if any further cerebrovascular events had developed.
resultsIn a combination of the two cohorts, the 10-year cumulative further cerebrovascular event rate was 9.5%, the incidence of angiographic disease progression was significantly higher in patients with further cerebrovascular events (100%) than in patients without (7%; p < 0.001), and the incidence of clopidogrel administration at last follow-up during or at the end of the 10-year follow-up was significantly higher in patients with declined cognition (100%) than in those without (21%; p < 0.001). Due to the small number of patients with further cerebrovascular events or declined cognition, multivariate statistical analysis was not performed.
conclusionThe 10-year cumulative further cerebrovascular event rate was <10% and angiographic disease progression may cause further cerebrovascular events in adult patients with ischemic MMD without cerebral misery perfusion who received nonsurgical management alone, including a reduction in atherosclerotic burden by medical treatment and antiplatelet therapy. Cognitive declines may develop in such patients without further cerebrovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.